NRAS is the most frequently mutated RAS isoform in melanoma and many hematologic malignancies, with a prevalence of approximately 20% to 40% in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) and juvenile chronic myelomonocytic leukemias [16–18]. Here, NRAS is linked to melanoma.